Leap Therapeutics, Inc. (NASDAQ:LPTX) Holdings Raised by Key Client Fiduciary Advisors LLC

Key Client Fiduciary Advisors LLC boosted its stake in Leap Therapeutics, Inc. (NASDAQ:LPTX) by 12.2% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 361,253 shares of the company’s stock after buying an additional 39,330 shares during the period. Key Client Fiduciary Advisors LLC owned 0.94% of Leap Therapeutics worth $1,039,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Valence8 US LP acquired a new stake in shares of Leap Therapeutics in the 3rd quarter worth approximately $48,000. HighTower Advisors LLC acquired a new stake in Leap Therapeutics in the third quarter worth approximately $65,000. HB Wealth Management LLC boosted its stake in Leap Therapeutics by 103.2% during the 4th quarter. HB Wealth Management LLC now owns 51,500 shares of the company’s stock valued at $150,000 after purchasing an additional 26,150 shares in the last quarter. Marshall Wace LLP increased its position in shares of Leap Therapeutics by 268.2% during the 2nd quarter. Marshall Wace LLP now owns 79,758 shares of the company’s stock valued at $156,000 after purchasing an additional 58,094 shares during the period. Finally, Exome Asset Management LLC bought a new stake in shares of Leap Therapeutics in the 3rd quarter worth $264,000. Institutional investors own 30.46% of the company’s stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and set a $5.50 target price on shares of Leap Therapeutics in a research note on Thursday, January 16th.

Leap Therapeutics Stock Performance

Shares of NASDAQ:LPTX opened at $2.20 on Friday. The stock has a market capitalization of $84.30 million, a price-to-earnings ratio of -1.14 and a beta of 0.17. Leap Therapeutics, Inc. has a 1-year low of $1.68 and a 1-year high of $4.79. The company has a 50 day moving average price of $2.93 and a 200 day moving average price of $2.77.

Leap Therapeutics Company Profile

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501.